このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Aurobindo Pharma バランスシートの健全性

財務の健全性基準チェック /66

Aurobindo Pharmaの総株主資本は₹298.5B 、総負債は₹63.2Bで、負債比率は21.2%となります。総資産と総負債はそれぞれ₹450.7Bと₹152.2Bです。 Aurobindo Pharmaの EBIT は₹43.2Bで、利息カバレッジ比率14.9です。現金および短期投資は₹63.3Bです。

主要情報

21.2%

負債資本比率

₹63.15b

負債

インタレスト・カバレッジ・レシオ	14.9x
現金	₹63.29b
エクイティ	₹298.51b
負債合計	₹152.21b
総資産	₹450.72b

財務の健全性に関する最新情報

These 4 Measures Indicate That Aurobindo Pharma (NSE:AUROPHARMA) Is Using Debt Reasonably Well

Nov 27

Recent updates

Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271

May 29

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

May 22

Aurobindo Pharma Limited's (NSE:AUROPHARMA) Earnings Are Not Doing Enough For Some Investors

Apr 10

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Worth ₹1.1k Based On Its Intrinsic Value?

Jan 14

Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet

Dec 27

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

Sep 07

Is Aurobindo Pharma (NSE:AUROPHARMA) A Risky Investment?

Jun 14

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Trading At A 29% Discount?

May 21

Aurobindo Pharma Limited's (NSE:AUROPHARMA) Intrinsic Value Is Potentially 93% Above Its Share Price

Feb 11

Aurobindo Pharma (NSE:AUROPHARMA) Seems To Use Debt Quite Sensibly

Jan 09

Is There An Opportunity With Aurobindo Pharma Limited's (NSE:AUROPHARMA) 50% Undervaluation?

Nov 02

We Think Aurobindo Pharma (NSE:AUROPHARMA) Can Stay On Top Of Its Debt

Jun 20

Calculating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)

Apr 14

Aurobindo Pharma's (NSE:AUROPHARMA) Dividend Will Be ₹1.50

Feb 11

Calculating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)

Jan 08

These 4 Measures Indicate That Aurobindo Pharma (NSE:AUROPHARMA) Is Using Debt Reasonably Well

Nov 27

Aurobindo Pharma's (NSE:AUROPHARMA) Upcoming Dividend Will Be Larger Than Last Year's

Nov 10

財務状況分析

短期負債: AUROPHARMAの短期資産 ( ₹242.1B ) が短期負債 ( ₹122.0B ) を超えています。

長期負債: AUROPHARMAの短期資産 ( ₹242.1B ) が長期負債 ( ₹30.2B ) を上回っています。

デット・ツー・エクイティの歴史と分析

負債レベル: AUROPHARMA総負債よりも多くの現金を保有しています。

負債の削減: AUROPHARMAの負債対資本比率は、過去 5 年間で49.7%から21.2%に減少しました。

債務返済能力: AUROPHARMAの負債は営業キャッシュフローによって十分にカバーされています ( 38.6% )。

インタレストカバレッジ: AUROPHARMAの負債に対する利息支払いは EBIT ( 14.9 x coverage) によって十分にカバーされています。

Aurobindo Pharma バランスシートの健全性

財務の健全性 基準チェック /66

主要情報

財務の健全性に関する最新情報

Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet

Is Aurobindo Pharma (NSE:AUROPHARMA) A Risky Investment?

Aurobindo Pharma (NSE:AUROPHARMA) Seems To Use Debt Quite Sensibly

We Think Aurobindo Pharma (NSE:AUROPHARMA) Can Stay On Top Of Its Debt

These 4 Measures Indicate That Aurobindo Pharma (NSE:AUROPHARMA) Is Using Debt Reasonably Well

Recent updates

Price target increased by 7.9% to ₹1,292

Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

Now 21% overvalued after recent price rise

Aurobindo Pharma Limited's (NSE:AUROPHARMA) Earnings Are Not Doing Enough For Some Investors

Aurobindo Pharma Limited Announces Retirement of K. Ragunathan as Chairman of Board of Directors, Effective March 31, 2024

Aurobindo Pharma Limited Appoints N. Ravikiran as Chief Business Officer

Insider recently sold ₹2.1m worth of stock

Less than half of directors are independent

Dividend reduced to ₹1.50

Aurobindo Pharma Limited Receives USFDA Approval for Deflazacort Tablets, 6 mg, 18 mg, 30 mg, and 36 mg

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Aurobindo Pharma Limited Approves the Resignation of Dr.(Mrs.) Avnit Bimal Singh as an Independent Director

Price target increased by 7.6% to ₹1,087

Price target increased by 7.5% to ₹1,085

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Worth ₹1.1k Based On Its Intrinsic Value?

Price target increased by 7.2% to ₹1,071

Insider recently sold ₹9.7m worth of stock

Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet

Insider recently sold ₹1.6m worth of stock

New minor risk - Insider selling

Price target increased by 10% to ₹956

Upcoming dividend of ₹3.00 per share at 0.3% yield

Aurobindo Pharma Limited Approves First Interim Dividend, Payable on or Before December 4, 2023

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Associate President of RAD- II recently sold ₹1.6m worth of stock

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

Aurobindo Pharma Limited Announces Interim Dividend for the Financial Year 2022-23

Price target increased by 8.2% to ₹721

Aurobindo Pharma Limited Announces Resignation of M. Sivakumaran as Whole-Time Director and Director

Full year 2023 earnings: EPS misses analyst expectations

Aurobindo Pharma Limited to Report Q2, 2024 Results on Nov 14, 2023

Aurobindo Pharma Limited Receives USFDA Approval for Saxagliptin Tablets, 2.5 Mg and 5 Mg

Aurobindo Pharma Limited, Annual General Meeting, Aug 25, 2023

Aurobindo Pharma Limited Announces Completion of US Fda Inspection At Unit III At Bachupally Village, Medchal Malkajgiri District, Telangana

Aurobindo Pharma Limited Announces Classification of US FDA Inspection At Unit XIV, Anakapalli District, Andhra Pradesh

Is Aurobindo Pharma (NSE:AUROPHARMA) A Risky Investment?

Price target increased by 9.0% to ₹643

Full year 2023 earnings: EPS misses analyst expectations

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Trading At A 29% Discount?

Insider recently sold ₹1.3m worth of stock

Insider recently bought ₹3.2m worth of stock

Aurobindo Pharma Limited's (NSE:AUROPHARMA) Intrinsic Value Is Potentially 93% Above Its Share Price

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Aurobindo Pharma Limited Approves First Interim Dividend, Payable on or Before March 3, 2023

Aurobindo Pharma (NSE:AUROPHARMA) Seems To Use Debt Quite Sensibly

Aurobindo Pharma Limited Announces Completion Of US FDA Inspection At Unit IX - Reg

Consensus EPS estimates fall by 15%

Price target decreased to ₹621

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Is There An Opportunity With Aurobindo Pharma Limited's (NSE:AUROPHARMA) 50% Undervaluation?

Insider recently sold ₹11m worth of stock

Insider recently sold ₹2.7m worth of stock

Aurobindo Pharma Limited (NSEI:AUROPHARMA) completed the acquisition of 34% stake in GLS Pharma Ltd from Suresh and Sunita Pathak.

Full year 2022 earnings: EPS and revenues miss analyst expectations

Aurobindo Pharma Limited to Report Q4, 2023 Results on May 30, 2023

Aurobindo Pharma Limited, Annual General Meeting, Aug 02, 2022

Aurobindo Pharma Limited, Annual General Meeting, Aug 02, 2022

We Think Aurobindo Pharma (NSE:AUROPHARMA) Can Stay On Top Of Its Debt

Teva Branded Pharmaceutical Products R&D, Inc. and Auspex Pharmaceuticals, Inc. Announces Settlement with Aurobindo to Resolve AUSTEDO® (deutetrabenazine) Patent Dispute

Consensus EPS estimates fall by 11%

Price target decreased to ₹734

Aurobindo Pharma Limited Announces Fourth Interim Dividend for the Financial Year 2021-22, Payable on or Before June 15, 2022

Full year 2022 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Calculating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)

Aurobindo Pharma Limited (NSEI:AUROPHARMA) agreed to acquire Domestic formulation business of Veritaz Healthcare from Veritaz Healthcare Limited for INR 1710 million.

財務の健全性基準チェック /66